ARCT Arcturus Therapeutics Holdings Inc

Price (delayed)

$38.76

Market cap

$1.04B

P/E Ratio

10.31

Dividend/share

N/A

EPS

$3.76

Enterprise value

$735.9M

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ ...

Highlights
The company's EPS has surged by 168% YoY and by 24% QoQ
The net income has soared by 168% year-on-year and by 24% since the previous quarter
Arcturus Therapeutics Holdings's debt has surged by 67% QoQ but it has decreased by 48% YoY

Key stats

What are the main financial stats of ARCT
Market
Shares outstanding
26.72M
Market cap
$1.04B
Enterprise value
$735.9M
Valuations
Price to book (P/B)
3.68
Price to sales (P/S)
3.48
EV/EBIT
8.05
EV/EBITDA
7.82
EV/Sales
2.48
Earnings
Revenue
$296.24M
EBIT
$91.46M
EBITDA
$94.16M
Free cash flow
$136.96M
Per share
EPS
$3.76
Free cash flow per share
$5.15
Book value per share
$10.53
Revenue per share
$11.15
TBVPS
$17.22
Balance sheet
Total assets
$457.65M
Total liabilities
$177.59M
Debt
$47.02M
Equity
$280.06M
Working capital
$305.59M
Liquidity
Debt to equity
0.17
Current ratio
4.49
Quick ratio
4.39
Net debt/EBITDA
-3.19
Margins
EBITDA margin
31.8%
Gross margin
100%
Net margin
33.5%
Operating margin
20.8%
Efficiency
Return on assets
22%
Return on equity
34.1%
Return on invested capital
222.6%
Return on capital employed
24.7%
Return on sales
30.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ARCT stock price

How has the Arcturus Therapeutics Holdings stock price performed over time
Intraday
-3.53%
1 week
3.53%
1 month
15.25%
1 year
138.52%
YTD
22.93%
QTD
22.93%

Financial performance

How have Arcturus Therapeutics Holdings's revenue and profit performed over time
Revenue
$296.24M
Gross profit
$296.24M
Operating income
$61.52M
Net income
$99.33M
Gross margin
100%
Net margin
33.5%
The net income has soared by 168% year-on-year and by 24% since the previous quarter
Arcturus Therapeutics Holdings's operating income has surged by 142% YoY and by 40% QoQ
Arcturus Therapeutics Holdings's net margin has surged by 112% YoY and by 10% QoQ
Arcturus Therapeutics Holdings's operating margin has surged by 107% YoY and by 25% QoQ

Growth

What is Arcturus Therapeutics Holdings's growth rate over time

Valuation

What is Arcturus Therapeutics Holdings stock price valuation
P/E
10.31
P/B
3.68
P/S
3.48
EV/EBIT
8.05
EV/EBITDA
7.82
EV/Sales
2.48
The company's EPS has surged by 168% YoY and by 24% QoQ
ARCT's P/E is 41% below its last 4 quarters average of 17.6
ARCT's equity has surged by 92% year-on-year
ARCT's P/B is 67% higher than its last 4 quarters average of 2.2 but 20% lower than its 5-year quarterly average of 4.6
ARCT's price to sales (P/S) is 92% lower than its 5-year quarterly average of 42.8 but 45% higher than its last 4 quarters average of 2.4
The revenue has grown by 12% since the previous quarter

Efficiency

How efficient is Arcturus Therapeutics Holdings business performance
The ROA has soared by 151% YoY and by 13% QoQ
The company's return on equity has surged by 142% YoY and by 9% QoQ
Arcturus Therapeutics Holdings's ROIC has soared by 138% YoY and by 21% from the previous quarter
The company's return on sales has surged by 111% YoY and by 8% QoQ

Dividends

What is ARCT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ARCT.

Financial health

How did Arcturus Therapeutics Holdings financials performed over time
Arcturus Therapeutics Holdings's total assets is 158% higher than its total liabilities
Arcturus Therapeutics Holdings's total assets has surged by 56% YoY and by 6% QoQ
ARCT's quick ratio is up by 39% year-on-year and by 4% since the previous quarter
Arcturus Therapeutics Holdings's debt is 83% lower than its equity
ARCT's equity has surged by 92% year-on-year
The debt to equity has plunged by 73% YoY but it has soared by 70% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.